TY  - JOUR
AU  - Machiels, Jean-Pascal
AU  - Salazar, Ramón
AU  - Rottey, Sylvie
AU  - Duran, Ignacio
AU  - Dirix, Luc
AU  - Geboes, Karen
AU  - Wilkinson-Blanc, Christine
AU  - Pover, Gillian
AU  - Alvis, Simon
AU  - Champion, Brian
AU  - Fisher, Kerry
AU  - McElwaine-John, Hilary
AU  - Beadle, John
AU  - Calvo, Emiiano
PY  - 2019
DO  - 10.1186/s40425-019-0510-7
UR  - http://hdl.handle.net/10668/3170
T2  - Journal for ImmunoTherapy of Cancer
AB  - Background: Enadenotucirev is a chimeric adenovirus with demonstrated preclinical tumor-selective cytotoxicity and a short half-life. Further clinical mechanism of action data showed that enadenotucirev can gain access to and replicate within...
LA  - en
PB  - BioMed Central Ltd
KW  - Clinical Trials
KW  - Pharmacokinetics and pharmacodynamics
KW  - Enadenotucirev
KW  - Oncolytic adenovirus
KW  - Epithelial solid tumor
KW  - Intravenous
KW  - Farmacocinética
KW  - Farmacología
KW  - Ensayos clínicos como asunto
KW  - Adenoviridae
KW  - Carcinoma
KW  - Inyecciones intravenosas
KW  - Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Drug Therapy::Drug Administration Routes::Administration, Intravenous
KW  - Medical Subject Headings::Organisms::Viruses::DNA Viruses::Adenoviridae
KW  - Medical Subject Headings::Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Peptides::Intercellular Signaling Peptides and Proteins::Cytokines
KW  - Medical Subject Headings::Persons::Persons::Age Groups::Adult
KW  - Medical Subject Headings::Disciplines and Occupations::Natural Science Disciplines::Biological Science Disciplines::Pharmacology
KW  - Medical Subject Headings::Phenomena and Processes::Chemical Phenomena::Biochemical Phenomena::Kinetics::Pharmacokinetics
KW  - Medical Subject Headings::Persons::Persons::Age Groups::Adult::Aged
KW  - Medical Subject Headings::Organisms::Viruses::Oncolytic Viruses
KW  - Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Biological Therapy::Oncolytic Virotherapy
TI  - A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE)
TY  - research article
ER  -